Friday, July 20, 2018 8:36:19 AM
Company: Novartis (NVS)
Therapy: Eltrombopag
Disease: Acute radiation syndrome
News: NVS announced in its earnings release that the FDA has granted its thrombopoietin analog eltrombopag Breakthrough Therapy designation for the treatment of acute radiation syndrome.
Looking forward: This builds on a body of evidence over the past decade that stimulation of bone marrow can help patients recover from the hematologic complications of radiation damage. Eltrombopag has the potential to recover lost platelets following radiation exposure, in particular. I imagine many are wondering what kind of impact this will have for companies like Pluristem (PSTI) that have cell therapies in development for the treatment of acute radiation syndrome. To that, I think it should be emphasized that eltrombopag is not likely to be a strong competitor, since there is a lot more that needs to be done to repair the damage done by radiation.
https://seekingalpha.com/article/4188636-3-things-biotech-july-20-specter-haunts-small-biotech
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM